Depression affects how your brain produces and uses energy. Research is increasingly pointing to mitochondrial dysfunction and neuroinflammation as factors in treatment-resistant depression, and NAD+ sits at the intersection of both. This article covers the biology, the clinical evidence, and what to realistically expect.<\/p>\n\n\n\n
Traditional models of depression focus on neurotransmitter imbalances (serotonin, dopamine, norepinephrine). But a growing body of research suggests that mitochondrial dysfunction plays a significant and possibly upstream role. When brain cells cannot produce enough energy, neurotransmitter synthesis slows, neuroplasticity decreases, and the brain’s ability to regulate mood deteriorates.<\/p>\n\n\n\n
NAD+ is the central molecule in mitochondrial energy production. Multiple studies have found that NAD+ levels are lower in people with major depressive disorder compared to healthy controls. Animal models of depression consistently show reduced NAD+ in brain tissue, and restoring NAD+ levels improves depression-like behavior in these models.<\/p>\n\n\n\n
The honest picture: the preclinical evidence for NAD+ in depression is strong. Human clinical trial data is limited but growing.<\/p>\n\n\n\n
NAD+ is not a replacement for mental health treatment<\/p>\n\n\n
If you are experiencing depression, work with a qualified mental health professional. NAD+ therapy may be a helpful adjunct, particularly for treatment-resistant cases, but it should not replace evidence-based treatments like therapy, medication, or other interventions like ketamine therapy<\/a> or TMS<\/a>.<\/p>\n\n<\/div><\/div>\n\n\n\n If you want to explore NAD+ for depression:<\/p>\n\n\n\nPractical Considerations<\/h2>\n\n\n\n
\n
Who Might Benefit Most<\/h2>\n\n\n\n